Adding Leucovorin to S-1 Improves PFS in Advanced Pancreatic Cancer

Share this content:

The addition of leucovorin to S-1 significantly improved progression-free survival compared with S-1 alone in patients with advanced pancreatic cancer who were refractory to gemcitabine, a study published online ahead of print in the journal Annals of Oncology has shown.1

For the study, researchers sought to evaluate the efficacy and safety of adding oral leucovorin to S-1 compared with S-1 monotherapy in patients with gemcitabine-refractory pancreatic cancer.

Researchers enrolled 142 patients and randomly assigned them 1:1 to receive S-1 40 to 60 mg orally based on body surface area plus leucovorin 25 mg orally, both twice daily for 1 week every 2 weeks, or S-1 monotherapy for 4 weeks every 6 weeks.

Results showed that median progression-free survival was 3.8 months in the combination arm compared with 2.7 months in the S-1 monotherapy arm (HR, 0.56; 95% CI: 0.37-0.85; P=.003). Researchers found that the disease control rate was 91% and 72% in the S-1 plus leucovorin arm and the S-1 monotherapy arm, respectively (P=.004).

Overall survival was 6.3 months in the leucovorin group and 6.1 months in the S-1 alone group (HR, 0.82; 95% CI: 0.54-1.22; P=.463), but researchers found that overall survival tended to be better in the combination arm after adjusting for patient background factors (HR, 0.71; 95% CI: 0.47-1.07; P=.099).

In regard to safety, both treatments were well tolerated, but gastrointestinal toxicities were slightly more severe in the combination arm.

The investigators note that a phase 3 trial is currently underway to further evaluate S-1 plus leucovorin in a similar setting.


1. Ueno M, Okusaka T, Omuro Y, et al. A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer [published online ahead of print December 17, 2015]. Ann Oncol. doi:10.1093/annonc/mdv603.
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs